SUMMARY
Infantile neuronal ceroid lipofuscinosis (INCL) is a fatal neurodegenerative disease caused by a deficiency in the lysosomal enzyme palmitoyl protein thioesterase-1 (PPT1). Ppt1 knockout mice display hallmarks of INCL and mimic the human pathology: accumulation of lipofuscin, degeneration of CNS neurons, and a shortened life span. Purified nongenetically modified human CNS stem cells, grown as neurospheres (hCNS-SCns), were transplanted into the brains of immunodeficient Ppt1 À/À mice where they engrafted robustly, migrated extensively, and produced sufficient levels of PPT1 to alter host neuropathology. Grafted mice displayed reduced autofluorescent lipofuscin, significant neuroprotection of host hippocampal and cortical neurons, and delayed loss of motor coordination. Early intervention with cellular transplants of hCNS-SCns into the brains of INCL patients may supply a continuous and long-lasting source of the missing PPT1 and provide some therapeutic benefit through protection of endogenous neurons. These data provide the experimental basis for human clinical trials with these banked hCNS-SCns.
INTRODUCTION
Neuronal ceroid lipofuscinosis (NCL), commonly referred to as Batten disease, belongs to a group of hereditary neurodegenerative lysosomal storage diseases (LSD) (reviewed in Mole, 2004; Wisniewski et al., 2001) . Among the nine identified forms of NCL, the infantile (INCL), late infantile (LINCL), and congenital (CNCL) forms are each caused by autosomal-recessive mutations of the genes that encode lysosomal enzymes. INCL results from mutations in the CLN1 gene, which encodes for palmitoyl protein thioesterase-1 (PPT1) (Das et al., 1998; Hofmann et al., 1999) . Deficiency of PPT1 results in the intracellular accumulation of lipofuscin, an autofluorescent lipoproteinaceous storage material that characterizes the pathology of this disease. Clinical symptoms, which begin as early as 6 months of age, manifest as a decline in cognitive and motor skills, visual impairment, seizures, and premature death. The development of a PPT1 knockout (Ppt1 À/À ) mouse model (Gupta et al., 2001 ) that recapitulates many aspects of its human disease counterpart, INCL, provides an experimental model for testing the potential therapeutic benefits of human neural stem cell transplant for the treatment of this disease. Enzyme replacement therapy (ERT), which ameliorates non-CNS symptoms for some LSDs, is not beneficial in treating CNS neurodegeneration, because intravenously administered enzymes can not cross the blood-brain barrier. Currently, there is no effective treatment available for any form of NCL. Here we take a novel approach of transplanting normal, nontumorigenic, and non-genetically modified banked human neural stem cells to provide secreted lysosomal targeted enzymes to a mouse model of NCL.
We have generated banks of expanded cells from prospectively isolated human central nervous system stem cells (hCNS-SC). Purification of cells by surface marker expression yields a highly purified neural stem cell population (Tamaki et al., 2002; Uchida et al., 2000) that is grown as neurospheres (hCNS-SCns, also known as HuCNS-SC) in serum-free defined media. We hypothesize that transplantation of hCNS-SCns directly into the brains of Ppt1 À/À mice will provide the deficient enzyme through secretion of PPT1 by these cells. PPT1 is captured via mannose-6-phospate receptors on the cell surface and is transported to lysosomes of target cells, where it participates in degrading accumulated toxic metabolites; this process is referred to as ''cross-correction.'' To test our hypothesis, Ppt1 À/À mice were backcrossed into immunodeficient NOD-SCID mice to generate the xenotransplant INCL mouse model (Ppt1
/NSCID) and a series of human neural stem cell transplantation studies were conducted.
In this study we describe the engraftment, neurogenesis, migration, and differentiation characteristics of hCNS-SCns transplanted into Ppt1 À/À /NSCID mice. These transplanted human hCNS-SCns migrated extensively, provided PPT1, reduced endogenous lipofuscin storage material, delayed the loss of motor coordination, and led to broad neuroprotection of host cells in the hippocampus and cortex.
RESULTS
In Vitro, hCNS-SCns Secrete the PPT1 that Is Internalized by Mutant CLN1 Fibroblasts via the Mannose 6-Phosphate Receptor To determine whether our cross-correction hypothesis would work with human neural stem cells, hCNS-SCns were cocultured for 7 days in a transwell system with fibroblasts derived from the Ppt1 À/À mouse and CLN1 patient. Secreted proteins can pass through the transwell without direct contact between hCNSSCns and fibroblasts. After coculture with hCNS-SCns, a significant increase and accumulation of intracellular PPT1 were observed in mutant fibroblasts derived from Ppt1 À/À mice (p < 0.0005) or a CLN1 patient (p < 0.05). Addition of a competitive inhibitor, mannose 6-phosphate, reduced PPT1 activity to basal levels in both Ppt1 À/À and CLN1 mutant fibroblasts ( Figures 1A and 1B). Thus, hCNS-SCns produce and secrete lysosomal PPT1 via the expected biochemical pathways for secretion and endocytosis in vitro. We expect that hCNS-SCns will exhibit this same mechanism of action to cross-correct enzyme-deficient host cells in vivo.
hCNS-SCns Engraft and Migrate in the Brain of Ppt1 À/À /NSCID Mice Next, we tested whether hCNS-SCns survive, migrate, and differentiate into different neural cell types in Ppt1 À/À /NSCID mice. Neonates received transplants into the anterior cortex, the lateral ventricle, and the cerebellum and were sacrificed at 20-27 weeks after transplant (almost at the end of their life span). Human cells were detected with either SC101 ( Figure 1C ) or SC121 ( Figure 1D ) antibodies, which recognize a nuclear and a cytoplasmic humanspecific antigen, respectively. Sagittal brain sections showed that the grafted cells were present in the subventricular zone (SVZ), the endogenous mouse stem/progenitor niche. In addition, a high density of human cells was detected in the rostral migratory stream (RMS), the normal migration route of endogenous neurogenesis in the olfactory system, and additionally in the cortex ( Figures 1C and 1D ).
Stereological counts of transplanted human cells were made from one hemisphere of five Ppt1 À/À /NSCID mice and six NOD-SCID mice. On average, 2 3 10 5 cells were detected in
Ppt1
À/À /NSCID mice, and NOD-SCID mice showed an average of 8.5 3 10 4 cells. In the hippocampus of Ppt1 À/À /NSCID mice, $9.0 3 10 4 cells were detected (Table S1 available (Figure 2A ), appeared astrocytic near the SVZ and corpus callosum ( Figure 2B ), and resembled oligodendrocytes in white matter tracts ( Figure 2C ). Cells in the cortex exhibited an undifferentiated morphology ( Figure 2D ), similar to the morphology of human cells in the cortex of normal Ppt1 +/+ /NOD-SCID mice. Lineage-specific staining was conducted, with Nestin as a marker for neural stem/progenitor cells and Doublecortin (DCX) and MAP2 for immature and mature neurons, respectively. As expected, human-specific Nestin (hNestin) identified a densely packed region of positive cells in the SVZ ( Figure 3A ). In the olfactory bulb, human neuronal cells double stained with SC121 and DCX ( Figure S4D ) or MAP2 ( Figure 3B ) were detected (see below for more details). The SVZ is a neurogenic niche composed of stem/progenitor cells undergoing cell division that can be detected with Ki67 antibody. Serial brain sections of transplanted Ppt1 À/À /NSCID mice revealed that, although there are many human cells in and around the SVZ ( Figure 3C ), only dispersed Ki67-positive cells are present ( Figure 3D ). The origin of these Ki67-positive cells (whether they are human or mouse) is not known because the Ki67 antibody used reacts with both species and human cells in the SVZ are too densely packed to evaluate individual cells. A quantitative assessment was performed to determine the proportion of proliferating human cells (i.e., SC121 + Ki67 + )
in the cortex. The assessment revealed that only rare human cells were Ki67 positive (2.6% ± 0.88% [SEM]) (Figures S2A and S2B, Table S2 ). These data suggest that proliferation of transplanted human cells in the Ppt1 À/À /NSCID mouse CNS is limited. Astrocytes play multiple roles in the formation of brain architecture and function. They associate with blood vessels to form the blood-brain barrier and form tunnels of cells to allow migration of neuroblasts in the RMS (Alvarez-Buylla and GarciaVerdugo, 2002; Kandel et al., 2000) ; they can also proliferate as reactive astrocytes that can induce gliosis or glial scarring (reviewed in Pekny and Nilsson, 2005) . The Alvarez-Buylla group has suggested that GFAP-positive cells in the SVZ are multipotent neural stem cells in both humans (Sanai et al., 2004 ) and adult mice (Doetsch et al., 1999) . We tested whether human cells of astrocytic lineage, defined by expression of GFAP, would participate in the same fashion as mouse astrocytes in our transplanted Ppt1 À/À /NSCID mice. Immunohistochemical staining of serial brain sections with SC121 revealed robust human engraftment ( Figure 3E ), whereas a human-specific GFAP antibody (hGFAP;SC123) showed limited staining and the few positive cells were restricted to the SVZ, RMS, and corpus callosum, with only occasional cells detected in the cortex ( Figure 3F ). When sections were costained with SC123 and an antibody to b-dystroglycan, a marker for mouse blood vessels, human GFAP-positive cells with astrocytic endfeet processes appeared in contact with a mouse b-dystroglycan-positive blood vessel (Figure 4A; Figures S3A and S3B) . This morphology is characteristic of astrocytes contributing to blood-brain barrier formation (Abbott, 2002 ).
Further, we tested whether the transplanted human cells cause gliosis in the Ppt1-deficient brain. For this purpose, double immunofluorescence staining was performed with SC121 and a GFAP antibody that reacts with both mouse and human GFAP. We counted approximately 1000 GFAP-positive cells and 200 SC121-positive human cells in the same cortical field of the cortex of the transplanted Ppt1 À/À /NSCID brain, revealing only a very small proportion of cells that were double positive (SC121 + GFAP + ) human astrocytes (Table S3) , with a few double-positive cells also detected in the fimbria and the SVZ. These results are similar to those observed in the hCNS-SCnstransplanted NOD-SCID mice (Guzman et al., 2007) ; based on these observations, it does not appear that transplanted hCNS-SCns cells contribute to gliosis in the brains of Ppt1 À/À / NSCID. Oligodendrocytes, another type of glial cell, were present in the white matter tracts of the corpus callosum and the anterior commissure, as defined by double fluorescence staining with an oligodendrocytes marker CC-1APC ( Figure 4B ).
The detection of human cells in the SVZ and RMS prompted us to examine whether they contributed to the architecture of the migratory pathway to the olfactory bulb. Sections were stained with SC121, SC123 (hGFAP), and DCX. Confocal analysis showed that hGFAP-positive cells were integrated within a tunnel of mouse astrocytes in the RMS where we observed migrating neuroblasts, as defined by DCX staining ( Figure 4C ; Figures  S4A-S4C ). Some of the migrating DCX-positive neuroblasts were SC121 + human cells ( Figure 4D ). When these migrating human cells were examined in the olfactory bulb, a quantitative analysis showed that approximately 17.4% (105 of 603 cells within three mouse brains) of the human cells expressed DCX ( Figure S4D ). In contrast, we did not observe any human cells that expressed DCX in the cortex of these samples. Moreover, some of the cells within the olfactory system differentiated further to mature neurons, as defined by MAP2 staining (Figure 3B ). In conclusion, even within a neurodegenerative environment, site-appropriate differentiation of hCNS-SCns is preserved and human astrocytes contributed to the architecture of both the blood-brain barrier and the RMS.
hCNS-SCns Do Not Induce Additional Inflammation in the Brain of Ppt1 À/À /NSCID Mice Inflammation has been identified as an important early event in the pathological cascade that eventually leads to the degeneration observed in the brains of Ppt1-deficient mice Kielar et al., 2007) . Transplants of human neural cells into Sandhoff mice (another mouse model for LSD) led to a reduction in inflammation in these brains (Lee et al., 2007) , and we wanted to see whether hCNS-SCns transplants exerted a similar effect on inflammation within the Ppt1 À/À /NSCID mouse brain.
Iba-1 staining is commonly used to monitor the presence of microglia and their activation. As expected, more activated microglia were present in the brains of the nontransplanted Ppt1 Having tested our cross-correction hypothesis in vitro, we next examined whether the hCNS-SCns can provide PPT1 to the brain of Ppt1 À/À /NSCID mice in a cell dose-dependent manner.
As expected, at 26 weeks of age, the Ppt1 À/À /NSCID brain displayed widespread accumulation of lipofuscin deposits, mostly in neurons. Characteristically, these deposits displayed autofluorescence, which can be easily identified ( Figures 5A-5C , arrowhead). SC121-positive human cells (red), which do not contain any autofluorescent storage material, were present in the vicinity of host neurons (arrow, Figures 5A-5C ). These transplanted cells expressed PPT1 (green), which was distributed in small granules presumably in the lysosomes of their cell bodies and processes. The engrafted human cells appear to sustain PPT1 expression after transplantation. However, because double immunofluoresce staining is hampered by neighboring autofluorescent cells, detection of PPT1 at the single cell level is challenging. Additional examples of PPT1-positive human cells are shown in Figure S5A as well as immunoperoxidase staining with the PPT1 antibody ( Figure S5B ). Nevertheless, we could not evaluate whether PPT1 could be taken up by host cells in vivo.
The residual level of PPT1 activity present in cell lines from CLN1 patients correlates directly with the age of onset, rate of progression, and severity of their disease phenotype (Das et al., 1998) . For example, CLN1 mutations associated with ''juvenile onset'' showed detectable enzyme activity $1%-2% of normal (Das et al., 2001) . Although a limited data set, the results suggest that low levels of PPT1 delay the onset of disease manifestation. Based on this study, we hypothesized that providing some level of PPT1 into the brains of Ppt1 À/À /NSCID mice could alter their disease progression.
To assess human cell engraftment and PPT1 activity, mice transplanted bilaterally with hCNS-SCns were sacrificed and their brains were dissected into hemispheres. The left hemispheres were processed for immunohistological staining and the right hemispheres were processed to measure PPT1 levels. In a pilot study, neonatal Ppt1 and evaluated at 18 weeks after transplant. Brain extracts from four of these animals had $0.8% ± 0.16% (SEM) of normal enzyme activity. In this study, the small size of the neonatal mouse brain (6 mm between anterior end of cortex and the posterior end of colliculus) limited the volume of cells that could be physically introduced at one time. Therefore to determine the effects of grafts with increasing numbers of cells, we designed a strategy that allowed administration of hCNS-SCns at multiple locations at different stages of disease progression. In the following quantitative studies, mice targeted for a low cell dose received transplants twice, first as neonates (P0-P1) and subsequently as juveniles. Mice receiving high cell doses were transplanted three times, as neonates, postnatally (P7), and as juveniles (see Supplemental Experimental Procedures and Table S4 for cell doses and transplantation scheme).
Brain extracts were prepared from low-and high-dose cohorts at 160-188 days after transplant, and PPT1 enzyme levels were quantified. Consistent with the original description of these mice (Gupta et al., 2001) , no detectable PPT1 was measured from control nontransplanted Ppt1 /NSCID mouse brains correlates with the hCNS-SCns cell dose. PPT1 activity was measured from whole brain extracts from 160-to 188-day-old Ppt1 À/À /NSCID mice. hCNSSCns were transplanted in either low (red, n = 7) or high (green, n = 11) cell doses. Enzyme activities are expressed as the mean ± SEM percentage of PPT1 activity of wild-type brain, which was set to 100%. In untreated Ppt1 À/À / NSCID mice, the PPT1 assay had a background level of 0.6% of the normal level found in wild-type mouse brain (n = 12). This background was subtracted from all samples to set the PPT1 activity in the nontransplanted Ppt1 
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Therapeutic Potential of Human Neural Stem Cells had a correspondingly higher level, up to 6.9% PPT1 at 160-188 days after transplant ( Figure 5D ). These data demonstrate that hCNS-SCns transplants provide measurable and longlasting levels of PPT1 activity in Ppt1 À/À /NSCID mice. These data do not prove that clinically meaningful levels of PPT1 reached host cells, but nevertheless these results encouraged us to undertake a histopathological analysis to evaluate the biological consequences of enzyme delivery via hCNS-SCns transplants in this preclinical model of disease.
Transplanted hCNS-SCns Contribute to a Decrease in the Autofluorescent Lipofuscin Material in the Brains of Ppt1
À/À /NSCID Mice One hallmark of both the Ppt1 À/À /NSCID mice and human INCL pathology is the accumulation of lipofuscin deposits throughout the brain. In mice, autofluorescence (AF) load is routinely used as a marker of disease progression (e.g., Griffey et al., 2004) , and we investigated whether transplanted hCNS-SCns would lead to a reduction in the host AF load. Quantitative confocal analysis of AF load in untransplanted Ppt1 À/À /NSCID mice (n = 4 at 162-169 day of age) was compared to that in transplanted agematched low-dose (1.5-1.8 3 10 6 cells; n = 3 at 167-170 days of age) mice. AF load was quantified as the average area that was autofluorescent per image field in scanned confocal images from the rostral and caudal portions of the cortex, the thalamus, the CA1 region of the hippocampus, and the cerebellum (see schematic sampling and analysis in Figure S5C and Supplemental Experimental Procedures). A significant reduction in AF load was observed in the low-dose group of mice for all areas of the brain measured (p = 0.0001) ( Figure 5E ). The reduction of storage material ranged from 31% in the cortex (CCtx) to 37% in the thalamus and more than 50% in the hippocampus and cerebellum when compared to the nontransplanted group. AF load was also measured in the high-dose cohort (2.8 3 10 6 cells; n = 3 at 188 days of age). No age-matched untransplanted controls were available because Ppt1 À/À /NSCID become moribund between 162 and 171 days (see below). Therefore, a cohort of mice aged 162-169 days was used for control. Significant reductions in storage deposits were also observed in all brain regions in the high-dose cohort, except for the thalamus (see individual p values in Figure S5D ). We know that disease progression and lipofuscin accumulation continue into the terminal stage of nontransplanted Ppt1 À/À /NSCID mouse, so it is likely that this comparison represents an underestimate of the AF load reduction in the high-dose cohort, because these mice were 17-26 days older that the control group. Nevertheless, transplantation of hCNS-SCns into Ppt1 À/À /NSCID significantly reduced AF storage material. Although this reduction of storage material was only partial, compared to control normal mice, we nevertheless explored whether hCNS-SCns transplants resulted in any downstream biological effects by examining neuronal survival.
Transplanted hCNS-SCns Prolong the Survival of Host Ppt1-Deficient Neurons and Delay the Loss of Motor Coordination
Having demonstrated in vivo production of PPT1 by hCNS-SCns and the concomitant reduction of AF storage material, we next examined whether these findings correlated with a neuroprotective effect on Ppt1-deficient host cells. Host neuronal survival was examined in nontransplanted control and transplanted Ppt1 À/À /NSCID mice ranging in age from 165 to 188 days, via staining for markers expressed by mature neurons, including calbindin, calretinin, and neural nuclear antigen (NeuN). NeuN is a DNA-binding protein expressed in the nuclei and perinuclear cytoplasm of most postmitotic neurons of mice, with the exception of Purkinje cells, mitral cells, and photoreceptors. NeuN expression was widely distributed in the cortex and hippocampus, and we identified an antibody to NeuN that preferentially stained mouse neurons over human neurons. SC121 and NeuN antibodies were used to double label brain sections analyzed by confocal microscopy. As expected, none of the SC121-positive human cells found in the cortex or hippocampus colocalized with NeuN staining (Figure S6A ), confirming that, under these conditions, NeuN staining is restricted to mouse cells. This NeuN staining of mouse cells was used to assess survival of host neurons in brain sections from NOD-SCID control mice ( Figure 6A ) and from nontransplanted (NT, Figure 6B ), low-dose ( Figure 6C ), and high-dose ( Figure 6D ) Ppt1 À/À /NSCID mice. There was significant loss of CA1 hippocampal neurons in Ppt1-deficient mice , and, as expected, the CA1 of nontransplanted Ppt1
/NSCID mice displayed greatly reduced NeuN staining compared to NOD-SCID control mice. In contrast, Ppt1 À/À /NSCID mice that received either a low or high cell dose displayed markedly more NeuN + CA1 neurons, indicating that the human cells were protecting the host neuronal cells in the hippocampus. To quantify this neuroprotective effect, we used image analysis to calculate the area of NeuN immunoreactivity in the CA1 region of each group and normalized these values to data from NOD-SCID mice ( Figure 6E ; Table 1 ). Only 8% of host CA1 region neurons survived in the nontransplanted Ppt1 À/À /NSCID controls, compared to NOD-SCID animals. In contrast, all hCNS-SCns transplanted mice had a significantly higher level of NeuN-positive neurons, with an average of 33% and 57% CA1 neurons surviving in the low and high cell dose groups, respectively ( Figure 6E , p < 0.001).
To determine whether these neuroprotective effects extended to other regions of the CNS, we also performed quantitative analyses of the survival of hippocampal CA2 and CA3 neurons and cortical neurons ( Figure S6B ). In Ppt1 À/À /NSCID mice receiving a low cell dose, NeuN-positive cells were found to be at 92% of normal levels and, for the high cell dose at 97% of normal (p < 0.001) (Table 1) , with significantly more (p < 0.05) NeuNpositive cortical neurons in these high cell dose animals (77% of normal, Table 1 ). A clear trend was observed correlating higher survival of host neurons with increased hCNS-SCns cell dose. Thus, hCNS-SCns can protect host neurons from degeneration in brains of Ppt1 À/À /NSCID mice, presumably by cross correction.
Rotarod testing provides a robust measure of cerebellar-associated motor deficits and reveals a progressively impaired performance in Ppt1 À/À mice (Griffey et al., 2006 ). An accelerating rotarod protocol was used to assess the performance of Ppt1 mice by week 17, whereas the Txp À/À group did not show a significant decline until week 18, indicating that hCNS-SCns transplantation delayed the loss of motor coordination.
DISCUSSION
More than 40 different LSDs have been identified, many affecting primarily peripheral organs that can be treated effectively by soluble adjuvant ERT. Unfortunately, more than half of the LSDs affect the CNS and these are recalcitrant to ERT because of the inability of the enzyme to cross the blood-brain barrier (Sly and Vogler, 2002) . To overcome this problem, one possible treatment strategy is direct administration of the missing enzyme into the CNS by either transplantation of donor cells that secrete the enzyme or by gene therapy targeting of the host cells. We have chosen to test transplants of long-term self-renewing human neural stem cell in this paradigm because these transplants can theoretically provide life-long production of the missing enzymes. Here, we provide proof of principle for this approach with hCNS-SCns supplying long-lasting delivery of PPT1 and neuroprotection in the Ppt1 À/À /NSCID mouse model of INCL, which is a profoundly disabling LSD.
Banked human neural stem cells are ideal cell candidates for treatment of LSD, because they can be cryopreserved and tested to ensure their quality for clinical use. Highly purified CD133 + , CD24 À/lo hCNS-SC directly isolated from fetal brain were characterized at the clonal level for their ability to selfrenew and differentiate into neurons and glia (Uchida et al., 2000) . These cells are selectively purified further by expansion in serum-free defined conditions to generate cell banks. These nontumorigenic, non-genetically modified hCNS-SCns have been transplanted into the brains of NOD-SCID mice and resulted in reproducible engraftment and extensive migration only within the CNS (Uchida et al., 2000) . Unlike embryonic stem cells, which can form teratomas, these brain-tissuederived somatic stem cells do not form tumors upon transplantation into the CNS (i.e., orthotopic sites) of NOD-SCID mice, immunosuppressed mice, rats, and nonhuman primates. We have transplanted more than 3000 immunodeficient mice to date and never found tumor formation from these cells (N.U., S.J.T., D.H., E. Apilado, K. Eckert, unpublished data). Also, no evidence of tumor formation was observed when hCNS-SCns were transplanted into the spinal cord of NOD-SCID mice or subcutaneously into flanks of nude mice. Taken together, our data reveal that hCNS-SCns can safely deliver therapeutic levels of PPT1 throughout the CNS, suggesting that this approach might be broadly applicable to other LSDs associated with enzyme deficiency, such as LINCL (CLN2).
The neuroprotection we observed in Ppt1 À/À /NSCID mice most probably resulted from local secretion of PPT1 by transplanted cells and its uptake by neighboring Ppt1-deficient cells. Both PPT1 activity and neuroprotection were correlated with the dose of hCNS-SCns and/or number of graft sites. Moreover, transplanted Ppt1 À/À /NSCID mice retained significantly better coordinated motor performance than nontransplanted mutant mice. However, we cannot exclude alternate mechanisms for neuroprotection, including elaboration of some neurotrophic factors, and/or modulating the inflammation associated with neurodegeneration, or replacement of host neurons and/or glia. Transplants of immortalized mouse or human neural cells have been made into a mouse model of Sandhoff disease (Lee et al., 2007) . These transplanted neural cells migrated extensively and appeared to cross-correct the Hexb À/À mouse brain and reduced CNS inflammation (Lee et al., 2007) . These data, taken together with our data from Ppt1-deficient mice, indicate that cell transplantation is a viable treatment for LSDs with CNS involvement. The potential of a gene therapy strategy with adenoassociated virus (AAV) to treat LSD with CNS involvement has been tested extensively in different animal models, including MPS IIV (Frisella et al., 2001) , Niemann-Pick (Passini et al., 2007) , CLN1 (Griffey et al., 2004 (Griffey et al., , 2005 (Griffey et al., , 2006 , and CLN2 (Cabrera-Salazar et al., 2007; Haskell et al., 2003) . With the integration of AAV into nondividing cells, lifelong provision of lysosomal enzymes in the CNS is possible, depending on the life span of the cells infected and/ or whether AAV also infects stem cells. One limitation of this approach is that enzyme production is restricted to the AAV injection sites, because the infected cells (e.g., neuronal cells) do not migrate.
In patients with Krabbe disease, another LSD with CNS involvement, it has been demonstrated that performing cord blood transplants at infancy, before disease manifestation, is crucial for obtaining clinical benefit (Escolar et al., 2005 (Escolar et al., , 2006 . Taken together, these studies provide sufficient evidence to believe that CLN1 patients could be treated most effectively by administrating the missing PPT1 via hCNS-SCns grafts into the affected brain early in disease progression. This early intervention would most likely result in better neuroprotection. In this paper, all groups were transplanted as neonates with hCNSSCns, although some mice received additional transplants 1 week later or as young adults. It is yet to be determined whether hCNS-SCns have a similar neuroprotective effect when they are transplanted into adult INLC mice.
The engrafted human cells of the glial lineage were found to have a normal tissue distribution and did not overgrow or contribute to astrocytic gliosis. Reactive astrocytosis has classically been thought to accompany or follow neuron loss, but in several LSDs, reactive changes are evident early in pathogenesis long before the onset of neuron loss (reviewed in Castaneda et al., 2008) . This phenotype is also evident in multiple forms of NCL (Oswald et al., 2005; Pontikis et al., 2004) , although the precise nature and timing of these events differs between forms of this disorder. In the Ppt1-deficient mice used in this study, localized astrocytosis precedes the progressive loss of relay neurons within individual thalamic nuclei, which was itself followed by a wave of microglial activation (Kielar et al., 2007) . It remains unclear whether this early astrocytosis is an attempted protective response, but these data are consistent with the idea that astrocytosis may also provide a sensitive marker of ongoing neuron dysfunction or damage (Raivich et al., 1999) . In our study, hCNS-SCns did not promote further inflammatory changes, as evaluated qualitatively by comparing the endogenous microglia between nontransplanted and transplanted brains. In addition, we demonstrated that a significant reduction in lipofuscin accumulation (by AF) was observed in the thalamus of transplanted animals. An interesting possibility would be if human PPT1 could also be provided by anterograde axonal transport (Griffey et al., 2005) , although it remains unclear how secreted PPT1 may be transported to host cells.
This study extends the surprising finding that transplanted hCNS-SCns integrate into the mouse brain and respond to the mouse brain structure with site-appropriate migration and differentiation. For example, in this INCL mouse model, many human astrocytes were found in the RMS, where they integrated and formed an astrocytic tunnel surrounding migrating mouse and human neuroblasts. Taken together, these observations suggest that hCNS-SCns can respond to local microenvironmental cues, even during neurodegeneration or injury.
hCNS-SCns have been transplanted into several other preclinical models. In stroke models, hCNS-SCns preferentially migrate toward the lesion border and differentiate toward the neuronal lineage (Cummings et al., 2005; Guzman et al., 2007; Kelly et al., 2004) , whereas in myelin-deficient shiverer mice, they differentiate into myelinating oligodendrocytes (Cummings et al., 2005) . In models of spinal cord injury, hCNS-SCns integrate, differentiate to oligodendrocytes, and remyelinate host axons or differentiate to form synapses. Most important is the . The Soft Imaging System image analysis software was used to quantify the area of NeuN-immunoreactivity in the CA1, CA2/3 subfields of the hippocampus and cortex. Results of the mean ± SEM area (mm 2 ) of NeuN staining in nontransplanted (n = 9), low cell dose (n = 6), and high cell dose (n = 6) Ppt1 demonstration that locomotion improvement directly correlates with the survival of human cells; loss of human cells results in loss of locomotor function (Cummings et al., 2005) . Further studies are in progress to characterize more extensively the therapeutic potential of hCNS-SCns in NCL disease and other diseases or traumatic injuries. For diseases such as LSDs, where a genetic mutation leads to a specific deficiency resulting in tissue destruction in peripheral organs and the brain, both systemic and CNS treatments will be required. Combination therapies might include enzyme infusion throughout life to both sites, hematopoietic cell transplants for the body and hCNSSCns transplants for the brain, viral-mediated gene therapy to both, or some combination of these approaches. Whatever methods in cell, gene, and protein therapies prove to be efficacious, these approaches will hopefully bring medical breakthroughs for these previously untreatable diseases. As a first step toward this goal, our data support our rationale for a phase I clinical trial in patients with INCL and LINCL.
EXPERIMENTAL PROCEDURES
hCNS-SCns Expansion hCNS-SCns were prospectively isolated from fetal brain tissue (16-20 gestational weeks) by flow cytometry and grown as neurospheres (hCNS-SCns), as described previously (Cummings et al., 2005; Uchida et al., 2000) . hCNS-SCns at passages 8-10 were used for the transplantation studies, having been demonstrated as karyotypically normal.
Generation of Ppt1
À/À /NSCID Mice and Transplantation All animal procedures were approved by the Institutional Animal Care and Use Committee at StemCells, Inc. Ppt1-deficient mice, described previously Gupta et al., 2001) , were provided by Sandra Hofmann (University of Texas Southwestern, TX). Ppt1 À/À mice were backcrossed onto the NOD-SCID background (i.e., Ppt1 À/À /NSCID), with all mice used in this study being from six backcross generations (N6) in most of the experiments, with the exception of rotarod testing, which used N10 generations of backcrosses. To achieve the desired cell dose levels, animals received transplants either solely as neonates or at multiple times. Details of the transplantation scheme, dose, and schedule are described in the Supplemental Experimental Procedures and Table S4 .
Determination of PPT1 Activities PPT1 assay were performed as described previously (Page et al., 1993; Sohar et al., 2000; Vines and Warburton, 1998; Voznyi et al., 1999) . PPT1-specific quenched fluorogenic substrates were used to assess the enzyme activity within protein extracts prepared from cell lines or tissues. To measure PPT1 activity in brains of transplanted mice, homogenates from the right hemispheres of Ppt1 À/À /NSCID mice were processed.
Immunohistochemical Analysis of Transplanted Mouse Brains
Transplanted mice were anesthetized and perfused with PBS followed by 4% paraformaldehyde (PFA). Mouse brains were sectioned sagittally with a microtome (Leica SM2400, Nussloch, Germany) at 40 mm thickness and stained with various antibodies to reveal the distribution of transplanted cells and subsequent effects upon the host CNS (see Supplemental Experimental Procedures).
For confocal immunofluorescence microscopy, imaging was performed on a Leica SP2 AOBS microscope (Leica Microsystems, Wetzlar, Germany). For characterization of lineage analysis, the resulting image stacks were analyzed with Volocity Software (Improvision, Coventry, UK). To confirm the colocalization of the labeled antigens within a cell, the fluorescent staining was inspected in the z-dimension via the orthogonal view tool.
Quantification of Autofluorescent Lipofuscin Deposits
As described previously, confocal microscopy was used to quantify the amount of autofluorescent storage material in Ppt1-deficient mice (Griffey et al., 2004 (Griffey et al., , 2005 (Griffey et al., , 2006 . All image acquisition and analyses were performed blind to treatment (Supplemental Experimental Procedure). Data were analyzed via one-way ANOVA followed by post-hoc Bonferroni analysis (SPSS, V 12.0) . Differences between control and treated (transplanted) groups were considered significant if p < 0.05.
Quantitation of NeuN-Positive Neurons in PPT1
À/À /NSCID Every sixth 40 mm sagittal section was stained immunohistochemically with mAb against NeuN. All histological sections utilized in this study were imaged with an Olympus BX61 microscope. Quantitative image analysis was performed with the Soft Imaging System (SIS) GmbH Biological Suite with Scopeview software. Detailed procedures for image acquisition, defining region of interest, and quantitative procedures are described in the Supplemental Data. All data points were analyzed by one-way ANOVA followed by the Bonferroni post-test.
Rotarod Test Ppt1
À/À /NSCID and their sibling Ppt1 +/À /NSCID NSCID mice from N10 generations of backcrosses received transplants of hCNS-SCns as described in Table S4 . Motor coordination was tested with a Rotarod apparatus (Accuscan Instruments, Columbus, OH) with acceleration (constant acceleration over 60 s from 0 to 15 rpm) with performance scored as time stayed on the rotarod (max 60 s) in three trials per session. Individual mice with known cohorts were tested weekly until Ppt1 mutant mice could no longer perform the test. Data were analyzed by repeated-measures ANOVA followed by post-hoc Bonferini post t test comparisons of individual time points of rotarod testing for Ppt1/ NSCID groups.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, six figures, and four tables and can be found with this article online at http:// www.cell.com/cell-stem-cell/supplemental/S1934-5909(09)00231-8.
